New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:05 EDTBSX, BAYRYBoston Scientific agrees to acquire Interventional division of Bayer for $415M
Boston Scientific (BSX) has entered into a definitive agreement to acquire the Interventional Division of Bayer AG (BAYRY) for $415M in cash, including fees for transitional services. The company expects to close the transaction in the second half of 2014, subject to customary closing conditions. The acquisition is expected to improve Boston Scientific's access to a number of attractive segments in the peripheral space, including the growing atherectomy and thrombectomy categories. In 2013, Bayer Interventional generated sales of approximately $120M. Upon completion of the transaction, Bayer Interventional will become part of the existing Boston Scientific Peripheral Interventions business. The agreement calls for an up-front payment of $415M. The company currently expects the transaction to be immaterial to adjusted earnings per share in 2014, accretive by approximately 1c in 2015 and increasingly accretive thereafter. On a GAAP earnings per share basis, the company expects the transaction to be slightly dilutive in 2014, immaterial in 2015, and less accretive than on an adjusted earnings per share basis thereafter as a result of acquisition-related net charges and amortization, which will be determined following the closing. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second half of 2014.
News For BSX;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
16:23 EDTBSXBoston Scientific announces strategic collaboration with Brainlab AG
Subscribe for More Information
15:04 EDTBSXNotable companies reporting before tomorrow's open
Subscribe for More Information
April 22, 2015
12:49 EDTBAYRYEU proposes new law that allows states to ban biotech crops, WSJ reports
Subscribe for More Information
07:07 EDTBAYRYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 20, 2015
16:09 EDTBSXBoston Scientific announces long-term data underscore safety, efficacy of S-ICD
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
07:44 EDTBSXSurvey shows strong momentum for Boston Scientific devices, says RBC Capital
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.
07:18 EDTBAYRYAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 16, 2015
16:11 EDTBSXBoston Scientific enrolls first patient REDUCE-HTN: REINFORCE study
Boston Scientific announced the first patient in the REDUCE-HTN: REINFORCE study was enrolled this week at Cardiology P.C. at Princeton Baptist Medical Center in Birmingham, AL by Farrell Mendelsohn, M.D., site principal investigator, and referred by Michael Wilensky, M.D. Boston Scientific received an investigational device exemption, or IDE, for the study from the FDA in December.
12:19 EDTBAYRYBayer downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
April 15, 2015
07:41 EDTBAYRYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
09:09 EDTBSXBoston Scientific announces strategic alliance with Frankenman
Boston Scientific announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader with deep local market expertise in the China surgical devices market. This alliance is expected to enable Boston Scientific and Frankenman to reach more clinicians and treat more patients by providing access to training on less invasive endoscopic technologies and the clinical and economic benefits these therapies can provide. CPEChina Fund, an entity of CITIC PE, is a current shareholder of Frankenman and will continue to support the company's growth in alignment with this strategic partnership.Under the terms of the agreement, Boston Scientific will become a shareholder of Frankenman, and provide services and expertise to Frankenman to support its continued growth, development pipeline and manufacturing capabilities. The transaction is expected to close in the first half of 2015, subject to customary closing conditions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use